Important Patent Extension government data with business impact

Notice 12 May 2025 regulatory review, patent extension, drug approval, pharmaceuticals, fda, healthcare

💊FDA Determines Regulatory Review Period for LITFULO Patent Extension

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LITFULO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

Learn More

Notice 12 May 2025 gilead sciences, regulatory review, patent extension, sunlenca, fda, pharmaceutical

💊FDA Notice on SUNLENCA Regulatory Review Period and Patent Extension

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SUNLENCA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

Learn More

Notice 12 May 2025 biotechnology, patent extension, regulatory compliance, pharmaceuticals, fda

💊FDA Regulatory Review Period Determination for LAMZEDE Patent Extension

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LAMZEDE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

Learn More

Notice 12 May 2025 patent extension, biotech, elrexfio, pfizer, fda, regulations, pharmaceutical, healthcare

💊FDA Determines Regulatory Review Period for ELREXFIO Patent Extension

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ELREXFIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

Learn More

Notice 12 May 2025 ngenla, health products, patent extension, regulatory compliance, fda, pharmaceutical

💊FDA Notice on NGENLA Regulatory Review Period and Patent Extension

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NGENLA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

Learn More

Notice 12 May 2025 regulation, patent extension, pharmaceuticals, fda, skyclarys, healthcare

💊FDA Announces Regulatory Review Period for SKYCLARYS Patent Extension

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SKYCLARYS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

Learn More